Global Plasma Therapy Market

Apheresis consumables and equipment are devices through which the blood drawn from a donor is separated into its components through plasma exchange, stem cell harvest, photopheresis, and low-density lipid removal techniques. Further, the required components like plasma or platelets are retained and the remaining is passed to the circulation. The main products of apheresis consumables and equipment are disposables and devices. The apheresis consumables are the products that are used in apheresis technology. The technologies involved in disposables and devices are centrifugation and membrane filtration and procedures involved are photopheresis, plasmapheresis, LDL apheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others. The apheresis consumables and equipment are used in applications such as renal disease, neurology, haematology, and others. The apheresis consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides apheresis consumables and equipment market statistics, including apheresis consumables and equipment industry global market size, regional shares, competitors with a apheresis consumables and equipment market share, detailed apheresis consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the apheresis consumables and equipment industry. This apheresis consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global apheresis consumables and equipment market grew from $2.65 billion in 2022 to $2.96 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The apheresis consumables and equipment market is expected to grow from $4.6 billion in 2027 at a CAGR of 11.6%. The cases of blood disorders are on the rise globally, creating a need for blood transfusions. Apheresis Equipment helps to transfuse blood for blood disorders like sickle cell anemia, leukemia, and cancer. According to a report published by Leukemia and Lymphoma Society, 60,300 people in the USA are expected to be diagnosed with leukemia, and one person is diagnosed with blood cancer every 3 minutes requiring an immediate blood transfusion. According to the American Society of Hematology, 100,000 Americans possessed sickle cell Anemia and another 2 million people carry the trait requiring Apheresis Equipment for blood transfusion. According to the International Agency for Research on Cancer (IARC), by 2040, 16.3 million new cancer cases are expected to be reported worldwide. Cancer treatment requires at least 8 units of blood per patient per procedure, thus requiring blood component collection and blood transfusion. Thus, such a high prevalence of these blood disorders increases demand for apheresis consumables and equipment. Lack of awareness about apheresis consumables and equipment restrains the apheresis consumables and equipment market. Patients in developing countries like Africa. and the Middle East are unaware of apheresis consumables and equipment and how the device can be advantageous to treating blood disorders and few lack access to the device at the medical facility due to high cost or unavailability. According to the journal of clinical apheresis, only Nigeria in the whole of West Africa. uses apheresis equipment to collect platelets. Most countries are unaware of the use of apheresis, leading to low demand for apheresis consumables and equipment, and hindering the growth of the market. Companies are developing technologically advanced and automated products that enhance the efficiency of the product (blood). Technologically advanced products like automatic apheresis equipment with continuous flow centrifugation, automated interface system, and customized anticoagulant infusion system are being developed and adopted. The adoption of automated Apheresis equipment has resulted in a more efficient and rapid blood separation process. For instance, Companies like Haemonetics Corp have developed automated apheresis equipment NexSys PCS that increases productivity and improves quality and compliance in plasma collection centres. Major players in the apheresis consumables and equipment market are Asahi Kasei Medical, Haemonetics Corporation, Kawasumi Laboratories Inc., Fresenius SE & Co. KGaA, Terumo BCT, FenwalInc., Braun Melsungen AG, TherakosInc., HemaCare Corporation, and Cerus Corporation. North America was the largest region in the apheresis consumables and equipment market in 2022. Western Europe was the second largest region in the global apheresis consumables and equipment market report. The regions covered in global apheresis consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the apheresis consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The apheresis consumables and equipment market consist of sales of equipment and consumables. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global apheresis consumables and equipment market is segmented - 1) By Product: Disposables, Devices 2) By Technology: Centrifugation, Membrane Filtration 3) By Application: Renal Disease, Neurology, Hematology, Other Applications 4) By Procedure: Photopheresis, Plasmapheresis, LDL Apheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, Other Procedures

Blood transfusion diagnostics are used to conduct tests before the transfusion of blood from donor-recipient such as blood grouping disease screening. The main types of blood transfusion diagnostics are instruments and kits, reagents, and others. The blood transfusion diagnostic kits are used to collect and transfuse blood. The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood transfusion diagnostics market research report is one of a series of new reports from The Business Research Company that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood transfusion diagnostics market grew from $3.65 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood transfusion diagnostics market is expected to grow from $5.68 billion in 2027 at a CAGR of 9.3%. Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., and Beckman Coulter Inc. North America was the largest region in the blood transfusion diagnostics market in 2022. Western Europe was the second largest region in the global blood transfusion diagnostics market. The regions covered in global blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Other Types 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening

Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism.It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes. The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global convalescent plasma therapy market size will grow from $0.04 billion in 2022 to $0.05 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global convalescent plasma therapy market size is expected to grow from $0.07 billion in 2027 at a CAGR of 12.0%. Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period. Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate. In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA will be observed. The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth. The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities. Different government authorities like the US FDA, CDSCO of India, and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication. In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access, and single-patient emergency only. Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition. COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications. The manufacturing process and shelf life should be the same as that of other similar plasma products. These strict guidelines framed by authorities are expected to limit the market growth. The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market. Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient. Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy. In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus. In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth. In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies. Under this collaboration, Grifols will collect plasma from FDA-approved plasma collection centres to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue). FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for public use. Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited and Orthosera Kft. North America was the largest region in the convalescent plasma therapy market in 2022. Western Europe was the second largest region in the global convalescent plasma therapy market. The regions covered in the global convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global convalescent plasma therapy market is segmented - 1) By Application: Prophylaxis, Treatment 2) By End-Users: Hospitals & Clinics, Laboratories & Research institutes 3) By Antibody type: IgM, IgG, IgA

Patient blood management is a patient-focused, evidence-based and systematic approach to optimize care of patients, who might need a blood transfusion, by optimizing patients’ blood, minimizing surgical blood loss, and harnessing the patient-specific physiological reserve of anemia thereby reducing the need for allogeneic blood transfusions. The patient blood management market is segmented by product into instruments, accessories, reagents and kits, software. The patient blood management kits are used to manage the patient’s blood. It is also segmented by component into plasma, whole blood, and red blood cells that are used for applications such as hospitals, clinics, and others. The patient blood management market research report is one of a series of new reports from The Business Research Company that provides patient blood management market statistics, including patient blood management industry global market size, regional shares, competitors with a patient blood management market share, detailed patient blood management market segments, market trends and opportunities, and any further data you may need to thrive in the patient blood management industry. This patient blood management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global patient blood management market grew from $12.82 billion in 2022 to $13.83 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The patient blood management market is expected to grow from $17.42 billion in 2027 at a CAGR of 6.0%. The rising number of accidents, trauma cases, and surgical procedures contributed to the growth of the global patient blood management market. According to WHO, 1.35 million people die every year due to road accidents, and low-income and middle-income countries account for 93% of the fatalities occurring in the world due to road accidents. According to the Centers for Disease Control and Prevention, in 2021, the caesarean birth rate was 32.1% of all the births. Increased number of accidents, trauma cases, and surgical procedures resulted in increased demand for blood, and its products are driving the global patient blood management market. The high cost associated with automated systems is expected to limit the growth of the global patient blood management market. Costs associated with an increasing regulatory requirement, infection testing, and hospital administration, which include initial project costs, personnel salaries, costs of equipment, outside resources, and ongoing project costs make automation expensive. According to the Researchgate, in 2022, the expected cost of transfusion of one unit of red cells is US$ 600–$1200. The high economic cost of automation is therefore expected to hamper the global patient blood management market. HEMAsavR is a sterile medical device to capture and transfer blood, which is increasingly being used to collect and salvage blood in surgical procedures and respond quickly to unanticipated blood loss. Clinicians can economically collect sterile, anticoagulated blood without any need for specialized resources. By this, the upfront shed blood collection cost decreases, allogenic transfusions can be avoided with improved outcomes such as decreased patient mortality, low incidence of infections, and reduced risk of multi-organ failure. Major players in the patient blood management market are Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Immucor Inc., B. Braun Melsungen AG, Macopharma, bioMérieux SA, Asahi Kasei Corporation, Kaneka Corporation, and Bio-Rad Laboratories Inc. North America was the largest region in the patient blood management market in 2022. Western Europe was the second largest region in the global patient blood management market report. The regions covered in the global patient blood management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the patient blood management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The patient blood management market includes revenues earned by instruments, blood processing devices, and centrifuges. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global patient blood management market is segmented - 1) By Product: Instruments, Accessories, Reagents And Kits, Softwares 2) By Component: Plasma, Whole Blood, Red Blood Cells 3) By Application: Hospital, Clinic, Other Applications

The extreme ultraviolet lithography are engaged in manufacturing extreme ultraviolet lithography systems that use the smallest wavelength to create circuits with small features and obtain an output with better resolution. The extreme ultraviolet lithography market covered in this report is segmented by equipment into the light source, mirrors, masks, and others; by the light source into laser-produced plasma, gas discharge, vacuum sparks; by end-user into integrated device manufacturers (IDM), foundry, others. The extreme ultraviolet lithography market research report is one of a series of new reports from The Business Research Company that provides extreme ultraviolet lithography market statistics, including extreme ultraviolet lithography industry global market size, regional shares, competitors with an extreme ultraviolet lithography market share, detailed extreme ultraviolet lithography market segments, market trends and opportunities, and any further data you may need to thrive in the extreme ultraviolet lithography industry. This extreme ultraviolet lithography market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global extreme ultraviolet lithography market size grew from $3.29 billion in 2022 to $4.04 billion in 2023 at a compound annual growth rate (CAGR) of 22.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The extreme ultraviolet lithography market size is expected to grow to $9.2 billion in 2027 at a CAGR of 22.9%. Increasing demand for smartphones is expected to boost the demand for the extreme ultraviolet lithography market. Extreme ultraviolet lithography (EUVL) is an advanced technology used for manufacturing more powerful microprocessors than traditional ones for smartphones and personal computers. EUV lithography helps build compact electronic chips with less complexity, reduced cost, and fewer power requirements. For instance, in March 2022, according to the Cybercrew article, a UK-based company association of tech-obsessed people that works on computers, mobile phones, and gaming, around 87% of adults owns smartphones in the year 2020 and with a global smartphone penetration rate of 78.9%, the UK is ranked second. Thus, increasing demand for more advanced smartphones creates a higher demand for EUV lithography to enable chipmakers to produce faster, smaller, and more powerful chips. The high price of extreme ultraviolet lithography systems may restrict the growth of the extreme ultraviolet lithography market. A lithography machine is one of the major tools in manufacturing chips. High-end lithography machines for cutting the most sophisticated chips are produced by only one company, ASML. The extreme ultraviolet lithography machine is made of more than 1,00,000 parts and costs about $120 million. Therefore, the high price of the systems may restrict the growth of the extreme ultraviolet lithography market. Companies operating in the market are continuously focusing on introducing new technologies to attract a large consumer base. For instance, Taiwan Semiconductor Manufacturing Company Limited (TSMC) introduced seven-nanometer plus (N7+), the first commercially available extreme ultraviolet (EUV) lithography technology in the industry, delivering consumer products to market in large volume. The N7+ method with EUV technology is built on TSMC’s successful 7nm node and covers the way for 6nm and high-level technologies. N7+ contributes 15% to 20% more density and increased power consumption than the N7 process, making it an increasingly popular choice for the industry’s next-wave outcomes. Major players in the extreme ultraviolet lithography market are ASML, Nikon, Canon, Intel Corporation, Samsung Electronics Co. Ltd., Taiwan Semiconductor Manufacturing Company Limited (TSMC), SUSS Microtec AG, Carl Zeiss AG, Toshiba, and Ultratech Inc. Asia-Pacific was the largest region in the extreme ultraviolet lithography market in 2022. North America was the second largest region in the electrical and electronics market. The regions covered in the extreme ultraviolet lithography market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the extreme ultraviolet lithography market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The extreme ultraviolet lithography market includes revenues earned by entities by providing electron optical lithography services, optical lithography, X-Ray lithography services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global extreme ultraviolet lithography market is segmented - 1) By Equipment: Light Source, Mirrors, Mask, Other Equipments 2) By Light Source: Laser-produced Plasma, Gas Discharge, Vacuum Sparks 3) By End User: Integrated Device Manufacturers (IDM), Foundry, Other End-Users

The mycoplasma testing detects mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample. The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. Polymerase chain reaction (PCR) detects mycoplasma species using primers specific for mycoplasma DNA, usually mycoplasma 16S rRNA genes. Enzyme-linked immunosorbent assay (ELISA) detects the presence of mycoplasma using either antibodies, or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods use a sample of the suspected cell culture which converts ADP to ATP using mycoplasmal enzymes. Deoxyribonucleic acid (DNA) staining detects the mycoplasma strain M. hyorhinis by growing a sample of suspected cell cultures with Vero cells, and staining the cells for DNA using a fluorescent dye. The different products in mycoplasma testing include instruments, assay, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end- of- production cell testing and is used by pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organizations, academic research institutes. The mycoplasma testing market research report is one of a series of new reports from The Business Research Company that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with a mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global mycoplasma testing market size grew from $0.81 billion in 2022 to $0.92 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mycoplasma testing market size is expected to grow to $1.47 billion in 2027 at a CAGR of 12.5%. The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneuminiae. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%. The lack of skilled/trained molecular biologists is expected to restrain the growth of the market in the forecast period. Mycoplasma testing requires specialized skillsets relating to life sciences, pharmaceuticals, electronics and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. Lack of trained manpower capable of performing the molecular biology experiments and interpreting the results is a major limitation in the testing and confinement of COVID-19 in developing countries. For the few laboratory experts present in these countries, priority is given to other medical emergencies such as heart attacks and road accidents. This shortage of skilled labor is expected to be a significant deterrent to the growth of the market during the forecast period. Major players operating in the market are undertaking various strategic investments such as the launch of innovative products, research and development advancements, and technological innovations, which are gaining significant popularity in the mycoplasma testing market. Companies are introducing new innovative products to meet the requirements of end-users and expand the consumer base to survive in the competitive business environment. For instance, in July 2020, bioMérieux, a France-based biotechnology company introduced Bio Fire Mycoplasma, an advanced test used for bio-therapeutics including hormones, antibodies, gene, and cell therapies for mycoplasma detection in pharmaceutical products. In January 2020, Charles River Laboratories International, Inc., a USA-based company specializing in a variety of preclinical and clinical laboratory services for the biotechnology, pharmaceuticals, and medical devices industry acquired HemaCare Corporation for approximately $380 million in cash. With the acquisition, Charles River Laboratories International, Inc. expands the scientific capabilities of the company in the high-growth cell therapy sector and HemaCare cellular products improve Charles River Laboratories ability to offer a comprehensive cell therapy solution, including mycoplasma detection. HemaCare Corporation is a USA-based company engaged in the production of human-derived biological products and services for cellular therapy development, drug discovery, and biomedical research. Major players in the mycoplasma testing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott, Roche Diagnostics, Boston Scientific Corporation, Clongen Laboratories LLC, Creative Bioarray, Nelson Laboratories Fairfield Inc., Norgen Biotek Corporation, Biotools B & M Labs S.A, GenBio, GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AngioDynamics, AtriCure Inc., CONMED Corporation, Olympus Corporation, Smith & Nephew, and Advanced Cardiac Therapeutics. North America was the largest region in the mycoplasma testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mycoplasma Testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mycoplasma testing market is segmented - 1) By Product: Instruments, Assay, Kits, and Reagents 2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies 3) By Application: Cell line Testing, Virus Testing, End- of- Production Cell Testing 4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes

The cold plasma is also referred to as non-thermal atmospheric pressure plasma and is used in industries such as plastics and polymers, textiles, electronics, food and agriculture, and medicine. Cold plasma is a reactive gas containing different amounts of ions, electrons, and neutral particles in the air that allows us to generate ozone from oxygen molecules by means of electrical discharges via atmospheric gases. The main types of cold plasma by regime are atmospheric cold plasma and low-pressure cold plasma. Atmospheric cold plasma is an ionized gas with a near room temperature. It is a source of reactive species, neutral particles, electromagnetic fields, and UV radiation that may be controlled. Cold plasma is used on the basis of technology, which includes remote treatment, direct treatment, and electrode contact. These are used for wood healing, blood coagulation, dentistry, cancer treatment, and other medical applications. Cold plasma is also used by end users such as automotive, electronics & semiconductors, food processing & packaging, medical, aerospace, and polymers & plastics. The cold plasma research report is one of a series of new reports from The Business Research Company that provides cold plasma statistics, including cold plasma industry global market size, regional shares, competitors with cold plasma shares, detailed cold plasma segments, market trends and opportunities, and any further data you may need to thrive in the cold plasma industry. This cold plasma research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cold plasma market size grew from $2.35 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 15.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The cold plasma market size is expected to grow to $4.99 billion in 2027 at a CAGR of 16.5%. The increased use of cold plasma technology across various industries is expected to propel the growth of the cold plasma market. Cold plasma technology is becoming more popular in medical and industrial applications such as healthcare devices and diagnostics. Cold plasma therapy is also being promoted as a viable treatment for the continuing COVID-19 outbreak. Cold plasma has the potential to kill bacteria, especially drug-resistant bacteria, preventing further infection and aiding in the treatment of chronic wounds. Cold plasma can help in the hydrophilization process in the textile industry in the treatment of protective clothing and sterile materials to reduce microorganisms. As per the German Federal Statistical Office 2020 report, there are about 83 million people in Germany, of which 16.2 million people are over 67 years of age, and it is projected to reach 21.4 million by 2040. With the increase in the geriatric population, there is also an increase in the diabetic population, which results in chronic wounds such as foot ulcers and thus boosts the overall market. Therefore, the increased use of cold plasma across various industries is driving the growth of the cold plasma market. Technological advancements are a key trend gaining popularity in the cold plasma market. Technological advancement is the advancement in technology. For instance, in June 2021, Nordson Corporation, a US-based developer and manufacturer of dispensing equipment, launched MARCH MegaVIATM Plasma Treatment System for large panels in printed circuit board manufacturing. The new MegaVIATM system delivers greater panel loading by more than 54% with only a 2% increase in footprint and overall dimensions of 1652mm W x 1782mm D x 2326mm H. High process reproducibility and plasma treatment uniformity for PCB panels are provided by the new platform. In July 2020, Grifols, a prominent developer of plasma-derived pharmaceuticals, acquired GC, Pharma Group's plasma fractionation unit and two purification units in Montreal, as well as 11 plasma collection centers in the United States for USD 460 million. This acquisition is aimed at expanding Grifols' plasma collection and fractionation capacity to enable access to plasma-derived medicines worldwide. GC Pharma (GC Pharma), a subsidiary of Green Cross Holdings Corp., provides plasma protein therapeutics and vaccines. Major players in the cold plasma market are Ethicon Inc., Baxter International Inc., 3M Company, Smith & Nephew plc., Nordson Corporation, Plasma Etch Inc., Adtech Plasma Technology Co., P2i Ltd., Relyon Plasma GmbH, Henniker Plasma, Enercon Industries, AcXys Plasma Technologies, Plasmatreat, Europlasma, SOFTAL, and UNIQAIR Technologies. Asia-Pacific was the largest region in the cold plasma market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cold plasma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold plasma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold plasma market consists of sales of cold plasma derived from techniques such as corona discharge and plasma jet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cold plasma market is segmented - 1) By Regime: Atmospheric Cold Plasma, Low-Pressure Cold Plasma 2) By Technology: Remote Treatment, Direct Treatment, Electrode Contact 3) By End Use Sector: Automotive, Electronics & Semiconductors, Food Processing & Packaging, Medical, Aerospace, Polymers & Plastics, Other End-User Sector 4) By Application: Wound Healing, Blood Coagulation, Dentistry, Cancer Treatment, Other Medical Applications